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a b s t r a c t 
The development of CFTR modulators has transformed the care of patients with cystic fibrosis (CF). Al- 
though the clinical efficacy of modulators depends on their concentrations in target tissues, the phar- 
macokinetic properties of these drugs in epithelia are not utilized to guide patient care. We developed
assays to quantitate ivacaftor in cells and plasma from patients on modulator therapy, and our analyses
revealed that cellular ivacaftor concentrations differ from plasma concentrations measured concurrently,
with evidence of in vivo accumulation of ivacaftor in the cells of patients. While the nature of this study is
exploratory and limited by a small number of patients, these findings suggest that techniques to measure
modulator concentrations in vivo will be essential to interpreting their clinical impact, particularly given





































Mutations in the Cystic Fibrosis (CF) Transmembrane conduc-
ance Regulator gene ( CFTR ) lead to dysfunction of the CFTR ion
hannel [1] . To ameliorate this dysfunction, new drugs have been
ntroduced: ivacaftor, a CFTR potentiator, used for surface localized,
ut dysfunctional CFTR channels [2] ; lumacaftor, a CFTR corrector
o partially correct the mutant F508del CFTR protein [3] ; tezacaftor,
n alternate corrector with a similar mechanism of action [4,5] ;
nd most recently, elexacaftor, a next generation corrector used in
ombination with tezacaftor [6,7] . Ivacaftor is included in all clin-
cally approved therapies alone and in combination with corrector
ompounds. For drugs that act within cells, tissue concentrations
re superior to plasma concentrations to model pharmacodynam-
cs [8–10] . As a hydrophobic molecule, ivacaftor has been shown
o accumulate in the inner leaflet of plasma membranes [11] and
n cultured airway epithelia [12] . Ivacaftor concentrations in ep-Abbreviations: CF, cystic fibrosis; CFTR, Cystic Fibrosis Transmembrane conduc- 
ance regulator.
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hat the concentrations used in most in vitro studies far exceed
he in vivo concentrations [13,14] . These concentrations may be
nfluenced by variability in plasma concentrations [15,16] . Under-
tanding the concentrations of ivacaftor in target tissues is critical
ecause high concentrations of ivacaftor are detrimental to CFTR
escue [12–18] . These findings suggest that determination of cellu-
ar and plasma ivacaftor concentrations would allow optimization
f dosing and additional mechanistic studies. To address this is-
ue, we developed a method to quantitate ivacaftor in plasma and
pithelial cells obtained from patients on modulator therapy. We
resent a pilot study with a limited number of patients showing
he feasibility of measuring ivacaftor in samples of cells directly
rom patients. 
. Methods
.1. Patient samples 
Written informed consent was obtained from nineteen sub-
ects recruited under protocols approved by the institution’s In-
titutional Review Board (F151030 0 01, University of Alabama at
irmingham). Plasma was collected from patients taking ivacaftor,























































































w  apy. The timing of sample collection after ingestion of drug was
not controlled. A subset of patients donated nasal epithelial cells
via brush biopsy (sterile 5 mm cytobrush, Medical Packaging Corp.,
Panorama, CA). Cells were lysed with NP-40 lysis buffer. Sam ples
were immediately processed with minimal handling and frozen at
−80 °C until analysis.
2.2. LC-MS/MS analysis 
Reference standards were purchased from commercial sources
providing certificates of analysis for all compounds compliant with
FDA regulations: ivacaftor, tezacaftor, and lumacaftor (SelleckChem,
USA); ivacaftor carboxylate (M6) and hydroxymethyl ivacaftor (M1)
(Clearsynth Canada Inc). M1 and M6-ivacaftor were selected be-
cause manufacturer testing showed that these are disproportion-
ate metabolites in humans and underwent further testing for reg-
ulatory approval [19] . Plasma assays were performed as previously
described [20] . Plasma and whole-cell lysate were extracted as pre-
viously described [12–20] . Peak area ratio (PAR) was calculated as
analyte relative to a stable internal standard and compared to a
standard curve of seven spiked concentrations of compound in ma-
trix (plasma or whole cell lysate). The resulting standard curve
data was fit to a weighted linear regression of 1/x 2 . Quality con-
trol (QC) samples across the concentration range were compared
with the standard curve; ≤15% difference between the QC and
standard curve was considered acceptable. Dynamic range of the
plasma assay is 1–10 0 0 ng/mL whereas that of the lysate assay
is 0.5–20 0 0 ng/mL. The average cell volume (1.6 pL) of nasal ep-
ithelial cells was determined by measurement of cells. Lysate con-
centrations were normalized to total cell volume within the sam-
ple, calculated from the number of cells multiplied by average vol-
ume per cell. Inter-day assay replicate bias and imprecision were
less than 8.36% for all three compounds; intra-day assay replicate
bias and imprecision were less than 10.55% maximum for all three
compounds. These values met the recommendations for bioanalyt-
ical methods by the FDA. We performed inter-day back calibra-
tion studies over a calibration range of 0.5–20 0 0 ng/mL (R values
> 0.999 in all runs for all compounds).
3. Results
3.1. Cellular quantitation of ivacaftor 
Cellular ivacaftor concentrations were measured in nasal biopsy
samples from subjects on CFTR modulator therapy. Lysate con-
centrations were measured and normalized to estimated total cell
volume in the sample ( Table 1 ). Ivacaftor was detected in all
subjects (range of 51.5–9.88 × 10 4 ng/mL cell vol). M1-ivacaftor
(pharmacologically active) was detected in five subjects (range of
42.5–1.65 × 10 5 ng/mL cell vol). M6-ivacaftor carboxylate (inactiveTable 1






A F508del/F508del Ivacaftor/lumacaftor 1 × 10 6 2.38
B F508del/F508del Ivacaftor/lumacaftor 1 × 10 6 0.68
F F508del/F508del Ivacaftor/tezacaftor 1 × 10 6 3.8
G F508del/F508del Ivacaftor/tezacaftor 2.5 × 10 5 148
H F508del/G551D Ivacaftor 1 × 10 6 16.3
I F508del/G551D Ivacaftor 2.5 × 10 5 327
J F508del/G551D Ivacaftor 2.5 × 10 5 84
Lysate concentrations are measured by immediate lysis of counted cells
number of cells are lysed in lysis buffer for each subject (cell number
volume of the cells in the sample. ND = Not Detected. VN = Volume No
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uggest an inability of these cells to produce the compound. 
.2. Comparison of plasma and cellular concentrations 
Plasma concentrations of modulators were determined to assess
heir influence on the cellular concentrations of ivacaftor ( Fig. 1 ,
able 2 ). The plasma concentrations for ivacaftor in the patients
n monotherapy were 500–2780 ng/mL; on ivacaftor/lumacaftor
9.6–256 ng/mL; and ivacaftor/tezacaftor 180 and 635 ng/mL. The
ariation seen in these patients may be attributed to time after
ngestion, and is within range of variation reported during reg-
latory review [19] . In patients taking ivacaftor/lumacaftor, mea-
ured values for lumacaftor were 1910–4950 ng/mL. In patients
aking ivacaftor/tezacaftor, tezacaftor concentrations were 774 and
070 ng/mL. No modulator compounds were detected in plasma
rom nine subjects not on CFTR modulators included as controls. In
ix of seven subjects who also contributed nasal biopsy, the plasma
oncentration was lower than the cellular concentration ( Table 2 ).
 positive correlation was observed between plasma and cellular
oncentrations ( Fig 1 C, Spearman r = 0.78, p = 0.048). No metabo-
ites of ivacaftor were detected in the cellular sample of the pa-
ients with highest cellular concentration of ivacaftor, which sug-
ests decreased metabolism and clearance in the cells of the pa-
ients. 
. Discussion
This study shows substantial differences between the plasma
nd cellular ivacaftor concentrations, and suggest different patterns
f metabolism in the epithelium compared to plasma. Although
e observed a correlation between plasma and cellular concen-
rations, this relationship was not constant, with evidence of dis-
roportionately elevated cellular concentrations in patients with
igher plasma concentrations. The cellular concentrations observed
re much higher than anticipated, but suggest in vivo accumulation
f ivacaftor similar to prior in vitro reports [12,21] and to cellular
ccumulation of fluoroquinolones, which are similar in structure
o ivacaftor [22] . These differences could result in a level of CFTR
estoration in target tissues distinct from what might be expected
rom plasma concentrations. There is a need to measure cellular
oncentrations of ivacaftor and other modulators in vivo to under-
tand patient exposures and place recent in vitro studies in context
f patient response. 
This study is limited by a small sample size and variable col-
ection times after drug dosing, which likely affects our results.
e suspect that cellular concentrations are likely more stable than
lasma due to decreased metabolism. The cell volume used is esti-
ated from measurements of cells in suspension, and is consistent
ith other reports of bronchial or nasal epithelial cell size [23,24] .1) in cells of patients taking CFTR modulators (raw and volume- 
Ivacaftor M1




4.47 × 10 4 ND ND
1.23 × 10 3 3.51 265
9.88 × 10 4 ND ND
2.54 × 10 4 545 1.65 × 10 5 
 after collection of nasal epithelial brush biopsy (raw). A known
). The raw concentrations are normalized to the estimated total
rmalized. 
 et al., Variable cellular ivacaftor concentrations in people with 
oi.org/10.1016/j.jcf.2020.01.011 
Fig. 1. Concentration of CFTR modulators. A . Cellular concentrations (open circles) of ivacaftor were normalized to average cell volume of human nasal epithelial cells
( Table 1 ). For patients taking ivacaftor, with ingestion around the expected time of peak plasma concentration, there was wide variation in concentration. Ivacaftor was
detected in all patients taking combination therapy ( Table 1 ). B. Ivacaftor demonstrates variable concentrations consistent with expectations for the different drugs, and also
variable concentrations among patients on the same therapy. Lumacaftor (black squares) is only detected in the patients taking ivacaftor/lumacaftor and tezacaftor (black
diamonds) in those taking ivacaftor/tezacaftor. C. Non-parametric Spearman correlation analysis between cellular and plasma concentrations of ivacaftor. All values reflect
ivacaftor concentrations, and the notation reflects the drug the patients are taking. Iva = Ivacaftor; Lum = Lumacaftor; Tez = Tezacaftor. Values plotted on log 10 scale. 
Table 2





(ng/mL) P/C ratio (ng/mL) (ng/mL)
A F508del/F508del Ivacaftor/lumacaftor 12.5 34.3 0.19 72.6 139
B F508del/F508del Ivacaftor/lumacaftor 14 29.6 0.57 129 409
C F508del/F508del Ivacaftor/lumacaftor 1 256 – 418 817
D F508del/F508del Ivacaftor/lumacaftor 8 114 – 464 2060
F F508del/F508del Ivacaftor/tezacaftor 14 180 0.63 350 225
G F508del/F508del Ivacaftor/tezacaftor 7 635 0.01 1660 1620
H F508del/G551D Ivacaftor 2.5 2780 2.26 3610 1520
I F508del/G551D Ivacaftor 4.25 804 0.01 3260 3780
J F508del/G551D Ivacaftor 6.5 500 0.02 783 201
Manufacturer’s C max 
∗ Ivacaftor/lumacaftor 602 – –
Manufacturer’s C max 
∗ Ivacaftor/tezacaftor 1170 – –
Manufacturer’s C max 
∗ Ivacaftor 768 – –
Subjects without nasal biopsy are included to assess variation of concentrations and to compare to the manufacturer’s data. Not all subjects
contributed a nasal biopsy (-). M1 = hydroxymethyl ivacaftor. M6 = ivacaftor carboxylate. ∗Manufacturer data from ivacaftor’s package insert pro- 
vided for reference. C max = mean maximum concentration. For samples above the dynamic range (1–10 0 0 ng/mL), they are diluted accordingly; 



























i  pithelial cell volume varies significantly between and within in-
ividuals, which could potentially influence our conclusions. The
mall sample size and variation in therapies also precluded us from
ssessing whether differences in plasma or cellular concentrations
ere associated with differences in clinical outcomes following ini-
iation of modulator therapy. Larger studies of patients with mul-
iple timed samples at steady state are needed to fully assess any
mpact of cellular concentration on clinical outcomes. Nonetheless,
hese findings strongly suggest that such studies are needed to de-
ermine the impact of CFTR modulator concentrations in vivo, es-
ecially as larger populations of patients with CF take triple com-
ination therapy including ivacaftor. 
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